Clearbridge Investments LLC Sells 171,891 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clearbridge Investments LLC lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 31.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 369,151 shares of the medical equipment provider’s stock after selling 171,891 shares during the period. Clearbridge Investments LLC owned 0.53% of Lantheus worth $33,024,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Cerity Partners LLC increased its stake in shares of Lantheus by 19.8% in the 3rd quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider’s stock valued at $1,306,000 after acquiring an additional 1,966 shares in the last quarter. Glenmede Trust Co. NA bought a new stake in Lantheus in the third quarter valued at $540,000. Captrust Financial Advisors raised its holdings in shares of Lantheus by 33.2% during the third quarter. Captrust Financial Advisors now owns 36,091 shares of the medical equipment provider’s stock valued at $3,961,000 after purchasing an additional 9,005 shares during the period. HighTower Advisors LLC bought a new position in shares of Lantheus during the 3rd quarter worth about $607,000. Finally, Janus Henderson Group PLC grew its stake in shares of Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 in the last quarter. 2.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Price Performance

Shares of LNTH stock opened at $97.93 on Wednesday. The firm has a 50-day moving average of $93.41 and a 200-day moving average of $96.28. Lantheus Holdings, Inc. has a one year low of $58.16 and a one year high of $126.89. The company has a market cap of $6.71 billion, a P/E ratio of 16.29 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.